BMS-986207
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for BMS-986207, covering 2024-02-28 to 2025-04-20. Get the full timeline:
Most recent: Clinical Trial Update: A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors [Phase 1, Phase 2]